In Italia oltre 100mila con patologie rare non diagnosticate
Search Results for: Malattia Arteriosa Periferica (PAD) - Indicazioni su diagnosi e gestione
Here's what we've found for you
Medication adherence of patients with peripheral arterial disease to antithrombotic therapy: a systematic review
Objectives
Antithrombotic therapy (ATT) prevents atherothrombotic events (AE) in patients with peripheral arterial disease (PAD). However, the benefit may be compromised by poor medication adherence (MA). Therefore, our primary objective was the proportion of patients with PAD with poor MA in literature following patient-reported, pharmacy-reported or laboratory-reported outcome measurements. Poor MA is a combined outcome of primary non-adherence (inability to initiate a prescription), secondary non-adherence (incorrect daily intake) and non-persistence (discontinuation of daily intake).
Design
Systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.
Data sources
PubMed, EMBASE and Cochrane Library were searched from 2000 to June 2023.
Eligibility criteria
Publications with a (sub)cohort of patients with PAD that reported on patients’ MA to ATT were included.
Data extraction and synthesis
All articles were reviewed on eligibility and methodological quality by two independent researchers. The data were retrieved and collected in Review Manager Web and the percentages were calculated per subgroup. The risk of bias was assessed by using the Cochrane risk-of-bias tool for randomised controlled trials (RCT) and the methodological index for non-randomised studies score for non-RCTs.
Results
We identified 274 potential records of which 10 studies (32 628 patients) were included. Six studies were RCTs and two prospective and two retrospective studies. Most studies scored a moderate risk of bias and had heterogeneous study designs. Poor MA rates ranged between 2% and 45%. Higher rates of poor MA were found in studies with longer follow-ups, pharmacy-reported outcome measurements and registry-based cohorts.
Conclusion
Heterogeneous study designs create a wide dispersion in the proportions. However, poor MA to ATT was found in approximately one-third of the patients with PAD and seemed to increase with longer therapy duration, which highlights the magnitude of this societal challenge. Enhancing patients’ MA to ATT might be a key element in reducing the risk of AE, and therefore, more attention to MA in clinical and research settings is warranted.
PROSPERO registration number
CRD42023431803.
Centro unico di Diagnosi prenatale eccellenza regionale
Nel 2024: +10% di ingressi. Il plauso sindaco di Loreto, Pieroni
Insufficienza renale, analisi suono limita interventi chirurgici
Grazie a monitoraggio fistole, diagnosi precoce complicazioni
Colangiocarcinoma,via corsi per medici per diagnosi precoci
In Italia 3500 casi anno fase avanzata,anche 6 mesi per diagnosi
Progetto Interceptor, i biomarcatori per predire la demenza
Dai primi risultati modello utile per la diagnosi precoce
Tumore del pancreas, sperimentato un test del sangue per la diagnosi precoce
Cruciale per questa neoplasia gravata dalla diagnosi tardiva
Un esame del sangue identifica il cancro al pancreas
Gli scienziati dell’Oregon Health & Science University hanno sviluppato PAC-MANN, un […]
La malattia irrompe al festival di Sanremo, 'il palco contro lo stigma'
Psichiatri e oncologi: ‘Da Balti a Fedez, messaggio di coraggio’
La malattia a Sanremo, 'il palco contro lo stigma'
Psichiatri e oncologi: ‘Da Balti a Fedez, messaggio di coraggio’
Tumore rene avanzato, con nuova terapia +11 mesi sopravvivenza
In Italia circa 13mila diagnosi carcinoma renale lo scorso anno
Tumore rene avanzato, con nuova terapia +11 mesi sopravvivenza
In Italia circa 13mila diagnosi carcinoma renale lo scorso anno
Mpox, ministero aggiorna le indicazioni su strategia vaccinale
Vaccino offerto a chi è a rischio per comportamenti o condizioni
Gestione farmacologica degli adulti con dislipidemia: linee guida
Questa linea guida pubblicata dall’American Association of Clinical Endocrinology, è […]
Epilessie nei bambini, nei giovani e negli adulti: linea guida
Questa linea guida pubblicata da NICE, riguarda la diagnosi e la […]
Alzheimer, un farmaco sperimentale ripristina la memoria e le altre funzioni cognitive
Un nuovo farmaco sperimentale, GL-II-73, sviluppato dal Centre for Addiction and Mental […]